Lilly/HMSS Humatrope agreement
HMSS will provide home I.V. services to all Humatrope (biosynthetic human growth hormone) patients, "including those with private insurance, Champus, qualified indigent, and Medicaid patients," the home health care company announced.
You may also be interested in...
Akcea Therapeutics has lowered its asking price in England for its antisense therapy for familial chylomicronaemia syndrome. It has also struck a pricing and reimbursement deal for the drug in Germany.
Fresenius Kabi must pay Eli Lilly €28m in damages after a French court of first instance found that the generics firm’s pemetrexed infringed intellectual property protecting the Alimta chemotherapy brand. The German firm has commented on possible next steps.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.